Hooda, Z, Ries, S, Fabian, T, Freeman, KA, Hofstetter, WL, Hudson, J, Mehran, RJ, Rajaram, R, Rice, DC, Swisher, SG , Vaporciyan, AA, Walsh, GL, Mitchell, KG, Zaku, B, Antonoff, MB
International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
Circadian Regulation: The peptide's influence on the pineal gland and its ability to normalise melatonin secretion and circadian rhythms in aged animal models
low-BMI twin-dyads ( Eubacterium , highlighting the importance of better mapping function and host-health implications at the genus and species level
